Nationally representative trends and geographic variation in treatment of localized prostate cancer: The Urologic Diseases in America project

Prostate Cancer and Prostatic Diseases

Volumn 18, Issue 2, 2015, Pages 149-154

  Cary, K C ^a   Punnen, S ^b   Odisho, A Y ^c   Litwin, M S ^d   Saigal, C S ^d   Cooperberg, M R ^c  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; COHORT ANALYSIS; CONTROLLED STUDY; CRYOTHERAPY; GEOGRAPHIC MAPPING; HUMAN; HUMAN TISSUE; ICD-9; INTENSITY MODULATED RADIATION THERAPY; LABORATORY TEST; LAPAROSCOPIC SURGERY; MAJOR CLINICAL STUDY; MALE; MEDICARE; MINIMALLY INVASIVE SURGERY; ONLINE ANALYSIS; PATIENT CARE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RADIODIAGNOSIS; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; UNITED STATES; BRACHYTHERAPY; GEOGRAPHY; PATHOLOGY; PROSTATIC NEOPLASMS; TRENDS; UROLOGIC DISEASES;

AGED; BRACHYTHERAPY; GEOGRAPHY; HUMANS; MALE; MEDICARE; PROSTATECTOMY; PROSTATIC NEOPLASMS; SEER PROGRAM; UNITED STATES; UROLOGIC DISEASES;

EID: 84929265895     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2015.3     Document Type: Article

References (21)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Thompson IM, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177: 2106-2131.
3. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71.
4. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 1117-1123.
5. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst 2006; 98: 839-845.
6. Nambudiri VE, Landrum MB, Lamont EB, McNeil BJ, Bozeman SR, Freedland SJ et al. Understanding variation in primary prostate cancer treatment within the Veterans Health Administration. Urology 2012; 79: 537-545.
7. Kawachi MH. Counterpoint: robot-assisted laparoscopic prostatectomy: perhaps the surgical gold standard for prostate cancer care. J Natl Compr Canc Netw 2007; 5: 689-692.
8. Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 2011; 29: 235-241.
9. Sun L, Caire AA, Robertson CN, George DJ, Polascik TJ, Maloney KE et al. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol 2009; 182: 2242-2248.
10. Herr HW, O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 2000; 163: 1743-1746.
11. Newton C, Slota D, Yuzpe AA, Tummon IS. Memory complaints associated with the use of gonadotropin-releasing hormone agonists: a preliminary study. Fertil Steril 1996; 65: 1253-1255.
12. Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-164.
13. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-4456.
14. Cookson MS, Sogani PC, Russo P. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. BJU Int 1997; 79: 432-438.
15. Krahn M, Bremner KE, Tomlinson G, Luo J, Ritvo P, Naglie G et al. Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use? BJU Int 2011; 108: 1588-1596.
16. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300.
17. D'Amico AV, Manola J, Loffredo M. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer. JAMA 2004; 292: 821-827.
18. Cooperberg MR, Cowan J, Broering JM, Carroll PR. High-risk prostate cancer in the United States, 1990-2007. World J Urol 2008; 26: 211-218.
19. Krupski TL, Kwan L, Afifi AA, Litwin MS. Geographic and socioeconomic variation in the treatment of prostate cancer. J Clin Oncol 2005; 23: 7881-7888.
20. Kramer KM, Bennett CL, Pickard AS, Lyons EA, Wolf MS, McKoy JM et al. Patient preferences in prostate cancer: a clinician's guide to understanding health utilities. Clin Prostate Cancer 2005; 4: 15-23.
21. Kapoor DA, Zimberg SH, Ohrin LM, Underwood W 3rd, Olsson CA. Utilization trends in prostate cancer therapy. J Urol 2011; 186: 860-864.